![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
December 04, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Oppenheimer 25th Annual Healthcare...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference
November 13, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Jefferies 2014 Global London Healthcare...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics Announces Third Quarter 2014 Financial Results
November 06, 2014 16:00 ET
|
Hyperion Therapeutics, Inc.
-- UCD Product Portfolio Generates $26.2 Million in Net Sales During the Quarter --
-- Company Delivers Fifth Consecutive Quarter of Adjusted Net Income --
-- Company to Host Conference Call...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6, 2014
October 31, 2014 09:00 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Oct. 31, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report third quarter 2014 financial results after market close on Thursday,...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics and Clal Biotechnology Industries Ltd. Enter Into Interim Agreement
BRISBANE, Calif. and RAMAT GAN, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) ("Hyperion") and Clal Biotechnology Industries Ltd. (TASE:CBI) ("CBI") today...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics to Present at the Leerink Rare Disease Roundtable
September 24, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Leerink Rare Disease Roundtable on...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics to Host Analyst Day September 30, 2014
September 23, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the Company will hold an Analyst Day on Tuesday, September 30, 2014, from 9:00 a.m....
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics Terminates DiaPep277(R) Program
September 08, 2014 08:00 ET
|
Hyperion Therapeutics, Inc.
Company Discovers Serious Misconduct by Andromeda Biotech Ltd.
Company to Host Conference Call Today at 9:00 a.m. ET (6:00 a.m. PT)
BRISBANE, Calif., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hyperion...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics Appoints Theodore Schroeder to Board of Directors
August 12, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the appointment of Theodore "Ted" Schroeder to its board of directors effective August 11,...
![Hyperion Logo](/news-release/logo/302957/0/302957.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A06&size=2)
Hyperion Therapeutics Announces Second Quarter 2014 Financial Results
August 07, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
UCD Product Portfolio Generates $37.1 Million in Net Sales During the Quarter
--$31.6 million of RAVICTI® recognized in the quarter including $11.7 million of previously deferred...